On February 11, 2021 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, reported that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO CEO & Investor Digital Conference being held February 16-18, 2021 (Press release, Cytori Therapeutics, FEB 11, 2021, View Source;Investor-Digital-Conference/default.aspx [SID1234574940]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s presentation will be made through the BIO CEO & Investor Digital Conference website and available on demand to registered participants during the conference at View Source Subsequent to the conference, the presentation will be made available under the ‘Events’ tab of the Investor Relations section of the Plus Therapeutics website at www.plustherapeutics.com.

In December, BIO and voter participants named Plus Therapeutics as this year’s Public Therapeutic Company "Buzz of BIO", recognizing the Company’s promising work developing novel therapies for rare and difficult to treat cancers, such as recurrent glioblastoma.